ADVAIR DISKUS 500/50
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADVAIR DISKUS 500/50 (ADVAIR DISKUS 500/50).
Salmeterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP, leading to bronchodilation. Fluticasone propionate is a corticosteroid with anti-inflammatory activity, inhibiting inflammatory cell infiltration and mediator release.
| Metabolism | Fluticasone propionate undergoes extensive first-pass metabolism via CYP3A4-mediated hydrolysis. Salmeterol is primarily metabolized by CYP3A4 to a hydroxylated metabolite. |
| Excretion | Fluticasone propionate: primarily hepatic (cytochrome P450 3A4) metabolism; renal excretion accounts for <5% as unchanged drug; fecal excretion accounts for the majority as metabolites. Salmeterol: primarily hepatic metabolism; renal excretion accounts for approximately 25% of the dose; fecal excretion accounts for approximately 60%. |
| Half-life | Fluticasone propionate: terminal elimination half-life is approximately 7.8 hours. Salmeterol: terminal elimination half-life is approximately 5.5 hours. Clinically, the half-life supports twice-daily dosing for sustained bronchodilation and anti-inflammatory effects. |
| Protein binding | Fluticasone propionate: >99% bound to plasma proteins (predominantly albumin and alpha-1-acid glycoprotein). Salmeterol: approximately 96% bound to albumin. |
| Volume of Distribution | Fluticasone propionate: approximately 4.2 L/kg; large Vd suggests extensive tissue distribution. Salmeterol: approximately 7 to 10 L/kg; large Vd indicates extensive tissue binding. |
| Bioavailability | Inhalation: Fluticasone propionate absolute bioavailability is approximately 13.9% (due to pulmonary deposition and oral absorption). Salmeterol absolute bioavailability is approximately 10% from the inhaled route; oral bioavailability is low (<1%) due to first-pass metabolism. |
| Onset of Action | Inhalation: Salmeterol has a slower onset of action (30 to 60 minutes) compared to short-acting beta-agonists; fluticasone propionate onset is delayed (days to weeks) for maximal anti-inflammatory effect. |
| Duration of Action | Inhalation: Salmeterol provides bronchodilation for approximately 12 hours; fluticasone propionate duration is dependent on regular dosing, with maximal benefit after 1-2 weeks of use. Clinical notes: Advair Diskus is indicated for twice-daily maintenance therapy, not for acute symptom relief. |
| Molecular Weight | Fluticasone propionate: 500.57 Da; Salmeterol: 603.75 Da (actual salt form: 415.6 Da for salmeterol base; Advair contains salmeterol xinafoate, MW 603.8). |
ADVAIR DISKUS 500/50: One inhalation (fluticasone propionate 500 mcg and salmeterol 50 mcg) twice daily (approximately 12 hours apart).
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for renal impairment; pharmacokinetics not significantly altered. |
| Liver impairment | Use with caution; no specific Child-Pugh based dose adjustments established. Monitor for systemic corticosteroid effects in severe hepatic impairment. |
| Pediatric use | Not recommended for children under 12 years. For ages 12 and older: same as adult dosing (500/50). Lower strengths available for initial therapy. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to increased risk of adverse effects (e.g., pneumonia, osteoporosis). Monitor carefully. |
| 1st trimester | Limited human data; animal studies show no teratogenic effects at inhaled doses. Potential risk of orofacial clefts with systemic corticosteroids in first trimester, but risk with inhaled fluticasone is low. Use only if benefit outweighs risk. |
| 2nd trimester | Inhaled corticosteroids are preferred for asthma control; salmeterol may cause fetal tachycardia. Use lowest effective dose. Monitor maternal asthma control closely. |
| 3rd trimester | Risk of neonatal adrenal suppression with prolonged high-dose fluticasone. Salmeterol may inhibit uterine contractions. Avoid high doses near term. |
Clinical note
Comprehensive clinical and safety monograph for ADVAIR DISKUS 500/50 (ADVAIR DISKUS 500/50).
| Placental transfer | Fluticasone propionate crosses placenta (low extent); salmeterol crosses placenta (unknown extent). Both are detectable in cord blood. |
| Breastfeeding | Fluticasone propionate and salmeterol are excreted in human milk in small amounts; clinical significance unknown. Use with caution in breastfeeding women, especially with high doses or prolonged use. Consider using a beta-agonist alone or inhaled corticosteroid alone if possible. |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. ADVAIR DISKUS is not indicated for treatment of acute bronchospasm.
| Serious Effects |
Hypersensitivity to fluticasone propionate, salmeterol, or any excipientStatus asthmaticus or acute asthma exacerbation requiring immediate interventionSevere hypersensitivity to milk proteins (device may contain lactose)
| Precautions | Asthma-related death risk with LABAs; not for acute symptoms; monitor for excessive beta-agonist adverse effects; cardiovascular effects; increased risk of pneumonia in COPD patients; adrenal insufficiency during corticosteroid withdrawal; immunosuppression; decreased bone mineral density; growth suppression in children; oropharyngeal candidiasis; paradoxical bronchospasm; hepatic impairment; drug interactions with strong CYP3A4 inhibitors. |
| Food/Dietary | Grapefruit and grapefruit juice may increase systemic exposure to fluticasone propionate and should be avoided. No other significant food interactions. Maintain adequate calcium and vitamin D intake due to ICS effect on bone density. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. Inhaled corticosteroids (fluticasone propionate) and long-acting beta-agonists (salmeterol) have been associated with teratogenic effects in animal studies, including cleft palate and delayed ossification at doses higher than therapeutic. Human data are limited; however, inadequate asthma control poses risks to both mother and fetus, including preeclampsia, preterm birth, and low birth weight. Use during pregnancy only if potential benefit justifies risk. Avoid use during first trimester if possible; monitor growth and development if used throughout pregnancy. |
| Fetal Monitoring | Monitor maternal: asthma control (peak flow, symptom scores), blood pressure, blood glucose (risk of hyperglycemia with beta-agonists), and signs of adrenal suppression or pneumonia. Fetal/neonatal: assess for intrauterine growth restriction (serial ultrasound), preterm labor, and neonatal hypoglycemia, hypocalcemia, or respiratory depression if used near term. |
| Fertility Effects | No known direct effects on human fertility. In animal studies, high doses of fluticasone and salmeterol have been associated with reduced fertility, but clinical significance is unknown. Uncontrolled asthma itself may contribute to infertility or pregnancy complications. |
| Clinical Pearls | ADVAIR DISKUS 500/50 is a high-dose ICS/LABA combination indicated for maintenance treatment of asthma or COPD. Not for acute bronchospasm. Rinse mouth after use to prevent oral candidiasis. Monitor for increased pneumonia risk in COPD patients. Do not use as monotherapy in asthma without ICS. Titrate to lowest effective dose. |
| Patient Advice | Use exactly as prescribed; do not use for sudden breathing problems. · Rinse mouth with water after each use to reduce risk of thrush. · Do not stop taking this medication without consulting your doctor. · Inform your doctor if you experience worsening symptoms or need more inhalations than usual. · Avoid exposure to measles or chickenpox; notify doctor if exposed. · Keep track of your peak flow readings as instructed. |